ZA200207994B - Pharmaceutical compositions including alginates. - Google Patents

Pharmaceutical compositions including alginates. Download PDF

Info

Publication number: ZA200207994B
Authority: ZA; South Africa
Prior art keywords: alginic acid; salt; composition; molecular weight; cell
Prior art date: 2000-03-10

Application number

ZA200207994A

Other languages

English (en)

Inventor

Dettmar Peter William

Jolliffe Ian Gordon

Hampson Frank Chadwick

Ross Peter Edward

Edvar Onsoyen

Mcpherson Paul Murray

Massimo Pignatelli

Raffaele Del Buono

Original Assignee

Reckitt Benckiser Healthcare

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-10

Filing date

2002-10-04

Publication date

2003-10-06

2002-10-04 Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare

2003-10-06 Publication of ZA200207994B publication Critical patent/ZA200207994B/en

Links

235000010443 alginic acid Nutrition 0.000 title claims description 110
229920000615 alginic acid Polymers 0.000 title claims description 110
239000008194 pharmaceutical composition Substances 0.000 title claims description 20
229960001126 alginic acid Drugs 0.000 claims description 74
239000000783 alginic acid Substances 0.000 claims description 74
150000004781 alginic acids Chemical class 0.000 claims description 61
150000003839 salts Chemical class 0.000 claims description 33
239000000203 mixture Substances 0.000 claims description 31
108060006698 EGF receptor Proteins 0.000 claims description 19
-1 alginic acid salt Chemical class 0.000 claims description 19
241000124008 Mammalia Species 0.000 claims description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
230000012202 endocytosis Effects 0.000 claims description 14
230000035876 healing Effects 0.000 claims description 14
102000001301 EGF receptor Human genes 0.000 claims description 12
238000000034 method Methods 0.000 claims description 10
230000009087 cell motility Effects 0.000 claims description 8
230000017455 cell-cell adhesion Effects 0.000 claims description 8
239000007788 liquid Substances 0.000 claims description 7
230000000638 stimulation Effects 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
239000011734 sodium Substances 0.000 claims description 6
229910052708 sodium Inorganic materials 0.000 claims description 6
239000000843 powder Substances 0.000 claims description 5
239000003755 preservative agent Substances 0.000 claims description 5
230000008569 process Effects 0.000 claims description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
239000008187 granular material Substances 0.000 claims description 4
AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
239000007910 chewable tablet Substances 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
239000004615 ingredient Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
229940068682 chewable tablet Drugs 0.000 claims description 2
238000004040 coloring Methods 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000005613 guluronic acid group Chemical group 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
239000011591 potassium Substances 0.000 claims description 2
229910052700 potassium Inorganic materials 0.000 claims description 2
239000000375 suspending agent Substances 0.000 claims description 2
239000002562 thickening agent Substances 0.000 claims description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
239000011777 magnesium Substances 0.000 claims 1
229910052749 magnesium Inorganic materials 0.000 claims 1
210000004027 cell Anatomy 0.000 description 42
230000006378 damage Effects 0.000 description 25
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 18
229940072056 alginate Drugs 0.000 description 18
230000002496 gastric effect Effects 0.000 description 18
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 15
230000000694 effects Effects 0.000 description 13
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 13
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 13
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 13
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 13
210000004877 mucosa Anatomy 0.000 description 13
102000009024 Epidermal Growth Factor Human genes 0.000 description 12
101800003838 Epidermal growth factor Proteins 0.000 description 12
241000700159 Rattus Species 0.000 description 12
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
229940116977 epidermal growth factor Drugs 0.000 description 12
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 11
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 11
235000010413 sodium alginate Nutrition 0.000 description 11
239000000661 sodium alginate Substances 0.000 description 11
229940005550 sodium alginate Drugs 0.000 description 11
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 10
208000027418 Wounds and injury Diseases 0.000 description 8
239000000796 flavoring agent Substances 0.000 description 8
235000019634 flavors Nutrition 0.000 description 8
210000002784 stomach Anatomy 0.000 description 8
229920001222 biopolymer Polymers 0.000 description 7
206010052428 Wound Diseases 0.000 description 6
229960000905 indomethacin Drugs 0.000 description 6
LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
238000010992 reflux Methods 0.000 description 6
235000017557 sodium bicarbonate Nutrition 0.000 description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
210000000981 epithelium Anatomy 0.000 description 5
235000003599 food sweetener Nutrition 0.000 description 5
210000001035 gastrointestinal tract Anatomy 0.000 description 5
230000005012 migration Effects 0.000 description 5
238000013508 migration Methods 0.000 description 5
210000000214 mouth Anatomy 0.000 description 5
239000003765 sweetening agent Substances 0.000 description 5
QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 4
229910000019 calcium carbonate Inorganic materials 0.000 description 4
230000001737 promoting effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
230000012292 cell migration Effects 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
229910000396 dipotassium phosphate Inorganic materials 0.000 description 3
235000019797 dipotassium phosphate Nutrition 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000003304 gavage Methods 0.000 description 3
229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
235000019796 monopotassium phosphate Nutrition 0.000 description 3
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
235000010226 sodium ethyl p-hydroxybenzoate Nutrition 0.000 description 3
239000004402 sodium ethyl p-hydroxybenzoate Substances 0.000 description 3
QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229920000161 Locust bean gum Polymers 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 2
241001406921 Squamosa Species 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
LCWAOCHOPBSGMU-UHFFFAOYSA-J aluminum;magnesium;sodium;hydrogen carbonate;oxygen(2-);silicon;trihydroxide Chemical compound [OH-].[OH-].[OH-].[O-2].[Na+].[Mg+2].[Al+3].[Si].OC([O-])=O LCWAOCHOPBSGMU-UHFFFAOYSA-J 0.000 description 2
229940069428 antacid Drugs 0.000 description 2
239000003159 antacid agent Substances 0.000 description 2
230000001458 anti-acid effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000002900 effect on cell Effects 0.000 description 2
229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
229940045140 gaviscon Drugs 0.000 description 2
208000014674 injury Diseases 0.000 description 2
235000010420 locust bean gum Nutrition 0.000 description 2
239000000711 locust bean gum Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
238000010232 migration assay Methods 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
239000002089 prostaglandin antagonist Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
230000028327 secretion Effects 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000011282 treatment Methods 0.000 description 2
239000000230 xanthan gum Substances 0.000 description 2
235000010493 xanthan gum Nutrition 0.000 description 2
229920001285 xanthan gum Polymers 0.000 description 2
229940082509 xanthan gum Drugs 0.000 description 2
VQJMAIZOEPPELO-KYGIZGOZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxy-5-methylhexan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol hydrochloride Chemical compound Cl.CO[C@]12CC[C@@]3(C[C@@H]1C(C)(O)CCC(C)C)[C@H]1Cc4ccc(O)c5O[C@@H]2[C@]3(CCN1CC1CC1)c45 VQJMAIZOEPPELO-KYGIZGOZSA-N 0.000 description 1
208000023514 Barrett esophagus Diseases 0.000 description 1
208000023665 Barrett oesophagus Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
229920003081 Povidone K 30 Polymers 0.000 description 1
102000004879 Racemases and epimerases Human genes 0.000 description 1
108090001066 Racemases and epimerases Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000000227 bioadhesive Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000008645 cold stress Effects 0.000 description 1
238000004624 confocal microscopy Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
230000002121 endocytic effect Effects 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229940041672 oral gel Drugs 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000011505 plaster Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229960001407 sodium bicarbonate Drugs 0.000 description 1
OGBHACNFHJJTQT-UHFFFAOYSA-M sodium;4-butoxycarbonylphenolate Chemical compound [Na+].CCCCOC(=O)C1=CC=C([O-])C=C1 OGBHACNFHJJTQT-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229950003937 tolonium Drugs 0.000 description 1
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ZA200207994A 2000-03-10 2002-10-04 Pharmaceutical compositions including alginates. ZA200207994B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0005743.0A GB0005743D0 (en)	2000-03-10	2000-03-10	Pharmaceutical compositions including alginates

Publications (1)

Publication Number	Publication Date
ZA200207994B true ZA200207994B (en)	2003-10-06

Family

ID=9887321

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200207994A ZA200207994B (en)	2000-03-10	2002-10-04	Pharmaceutical compositions including alginates.

Country Status (14)

Country	Link
US (1)	US7776839B2 (pt)
EP (1)	EP1265623B1 (pt)
CN (1)	CN1265798C (pt)
AT (1)	ATE268181T1 (pt)
AU (2)	AU2001244298B2 (pt)
BR (1)	BR0109139B1 (pt)
CA (1)	CA2402449C (pt)
DE (1)	DE60103619T2 (pt)
ES (1)	ES2217126T3 (pt)
GB (2)	GB0005743D0 (pt)
MX (1)	MXPA02008842A (pt)
PL (1)	PL200402B1 (pt)
WO (1)	WO2001066119A2 (pt)
ZA (1)	ZA200207994B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0012094D0 (en) *	2000-05-19	2000-07-12	Reckitt & Colmann Prod Ltd	Pharmaceutical compositions
GB2398496A (en) *	2003-02-20	2004-08-25	Reckitt Benckiser Healthcare	Suspensions of water-swellable polymer particles which are substantially water-free or contain insufficient water to fully swell the particles
TR200300510A2 (tr) *	2003-04-18	2004-11-22	Sanovel �La� Sanay� Ve T�Caret A.�.	Dağılan alendronat mikropartikül formülasyonu
SE530184C2 (sv) *	2005-12-23	2008-03-18	Kjell Stenberg	Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
EP1859786A1 (en) *	2006-05-16	2007-11-28	Frutarom Netherlands B.V.	A method to reduce the symptoms of heartburn and gastro-oesophageal reflux disease (GERD) by specific polysaccharides
AU2007317780B2 (en)	2006-11-07	2013-06-13	The Procter & Gamble Company	Fiber containing compositions and methods of making and using same
US7767248B2 (en)	2007-02-02	2010-08-03	Overly Iii Harry J	Soft chew confectionary with high fiber and sugar content and method for making same
WO2009068841A2 (en)	2007-11-27	2009-06-04	Algipharma Ipr As	Use of alginate oligomers in combating biofilms
JP5202764B2 (ja)	2009-06-03	2013-06-05	アルギファルマエーエス	細菌における多剤耐性の克服に使用されるアルギネートオリゴマー
DE102016113017A1 (de)	2016-07-14	2018-01-18	Abbas Mirshafiey	Pharmazeutische Verwendung von alpha-L-Guluronsäure
DE102016113018A1 (de)	2016-07-14	2018-01-18	Abbas Mirshafiey	Pharmazeutische Verwendung von beta-D-Mannuronsäure

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1524740A (en) *	1976-11-09	1978-09-13	Reckitt & Colmann Prod Ltd	Pharmaceutical compositions for use in the suppression of gastric reflux
GB2093697A (en) *	1980-09-03	1982-09-08	Kyosei Pharmaceutical Co Ltd	Agent for alimentary canal
JPS5746920A (en) *	1980-09-03	1982-03-17	Kyosei Seiyaku Kk	Drug for digestive tract
GB2222772B (en) *	1988-09-20	1992-05-13	Glaxo Group Ltd	Pharmaceutical compositions
AU7221691A (en) *	1990-01-23	1991-08-21	Terje Espevik	Mannuronic acid containing alginate wound healing composition and method
JP2643669B2 (ja) *	1990-12-28	1997-08-20	共成製薬株式会社	アルギン含有食品
DE4204012A1 (de) *	1992-02-12	1993-08-19	Ulrich Prof Dr Zimmermann	Mitogenfreie substanz, deren herstellung und verwendung
US5266326A (en) *	1992-06-30	1993-11-30	Pfizer Hospital Products Group, Inc.	In situ modification of alginate
US5510102A (en) *	1995-01-23	1996-04-23	The Regents Of The University Of California	Plasma and polymer containing surgical hemostatic adhesives
JP2001509167A (ja) *	1997-01-24	2001-07-10	エイブイアイバイオファーマ，インコーポレイテッド	Ｈ．ｐｙｌｏｒｉ感染を処置するための方法および結合体
GB9708772D0 (en) *	1997-04-30	1997-06-25	Reckitt & Colmann Prod Ltd	Organic compositions
WO1998048814A1 (en) *	1997-04-30	1998-11-05	Reckitt & Colman Products Limited	Pourable alginate compositions
GB9708773D0 (en) *	1997-04-30	1997-06-25	Reckitt & Colmann Prod Ltd	Organic compositions
JP2001520274A (ja) *	1997-10-17	2001-10-30	アドバンスト・メディカル・ソリューションズ・リミテッド	発泡材料

2000
- 2000-03-10 GB GBGB0005743.0A patent/GB0005743D0/en not_active Ceased
2001
- 2001-03-09 DE DE60103619T patent/DE60103619T2/de not_active Expired - Lifetime
- 2001-03-09 MX MXPA02008842A patent/MXPA02008842A/es active IP Right Grant
- 2001-03-09 AT AT01917211T patent/ATE268181T1/de not_active IP Right Cessation
- 2001-03-09 PL PL360122A patent/PL200402B1/pl not_active IP Right Cessation
- 2001-03-09 AU AU2001244298A patent/AU2001244298B2/en not_active Ceased
- 2001-03-09 GB GB0105837A patent/GB2362103B/en not_active Expired - Fee Related
- 2001-03-09 AU AU4429801A patent/AU4429801A/xx active Pending
- 2001-03-09 CN CNB01807488XA patent/CN1265798C/zh not_active Expired - Fee Related
- 2001-03-09 EP EP01917211A patent/EP1265623B1/en not_active Expired - Lifetime
- 2001-03-09 BR BRPI0109139-5B1A patent/BR0109139B1/pt not_active IP Right Cessation
- 2001-03-09 CA CA2402449A patent/CA2402449C/en not_active Expired - Fee Related
- 2001-03-09 ES ES01917211T patent/ES2217126T3/es not_active Expired - Lifetime
- 2001-03-09 WO PCT/GB2001/001026 patent/WO2001066119A2/en active IP Right Grant
2002
- 2002-09-10 US US10/241,048 patent/US7776839B2/en not_active Expired - Fee Related
- 2002-10-04 ZA ZA200207994A patent/ZA200207994B/en unknown

Also Published As

Publication number	Publication date
PL360122A1 (en)	2004-09-06
GB2362103B (en)	2002-10-16
BR0109139A (pt)	2002-12-03
ES2217126T3 (es)	2004-11-01
ATE268181T1 (de)	2004-06-15
CA2402449A1 (en)	2001-09-13
EP1265623B1 (en)	2004-06-02
EP1265623A2 (en)	2002-12-18
AU2001244298B2 (en)	2004-10-21
CN1420780A (zh)	2003-05-28
DE60103619T2 (de)	2005-06-16
GB0105837D0 (en)	2001-04-25
WO2001066119A2 (en)	2001-09-13
US20030130229A1 (en)	2003-07-10
PL200402B1 (pl)	2009-01-30
WO2001066119A3 (en)	2002-03-14
GB0005743D0 (en)	2000-05-03
MXPA02008842A (es)	2003-04-25
DE60103619D1 (de)	2004-07-08
GB2362103A (en)	2001-11-14
US7776839B2 (en)	2010-08-17
AU4429801A (en)	2001-09-17
BR0109139B1 (pt)	2013-09-03
CN1265798C (zh)	2006-07-26
CA2402449C (en)	2011-02-15

Publication	Publication Date	Title
ES2251997T3 (es)	2006-05-16	Composiciones adhesivs a la mucosa para el tratamiento de transtornos del esofago y su uso.
US5667802A (en)	1997-09-16	Antacid composition
EP1265623B1 (en)	2004-06-02	Pharmaceutical compositions including alginates
KR20040089628A (ko)	2004-10-21	생체내에서 상전이하는 액상 매트릭스 및 액상 경구 제제
AU2001244298A1 (en)	2001-11-29	Pharmaceutical compositions including alginates
KR20010020438A (ko)	2001-03-15	주입가능한 알기네이트 조성물
JPH0723318B2 (ja)	1995-03-15	製剤組成物
KR19980702689A (ko)	1998-08-05	알긴산나트륨 및 중탄산칼륨을 포함하는 액체 수성 약제학적조성물
CN114225010A (zh)	2022-03-25	含有rh-bFGF的口腔溃疡膜贴剂及其制备方法
GB2324725A (en)	1998-11-04	Alinate/Alginic Acid Composition
JPH08512321A (ja)	1996-12-24	Ｈ▲下２▼拮抗剤−アルギネート−制酸剤の組合せ物
JP2004002320A (ja)	2004-01-08	生体内で相転移する液状マトリックスおよび液状経口製剤
US20030176394A1 (en)	2003-09-18	Pepsin inhibition by alginates
WO2003037355A1 (en)	2003-05-08	Polyacrylate compositions for use in protecting mucosa
AU2001258538A1 (en)	2002-02-14	Pepsin inhibition by alginates
US20230398136A1 (en)	2023-12-14	Compositions and methods for treating diseases associated with drug washout due to fluid secretion
US20230320983A1 (en)	2023-10-12	New compositions of sucralfate in alginate and their use in therapy
US20160287627A1 (en)	2016-10-06	Method for suppressing onset of gastric ulcer as adverse effect of drug, oral pharmaceutical composition for suppressing onset of gastric ulcer and method for producing the same
RU2330671C1 (ru)	2008-08-10	Способ профилактики язвенных поражений желудка, вызванных приемом нестероидных противовоспалительных средств
Goel et al.	2008	Drugs Acting on Gastrointestinal System
Principal	0	Oral In-Situ Gel: A Review